Dexcom INC Schedule 13G passive stakes

Vanguard Capital Management has filed a Schedule 13G reporting a 7.49% beneficial ownership stake in Dexcom Inc.

Vanguard Portfolio Management reports beneficial ownership of over 19.3 million shares, representing 5.02% of Dexcom Inc.'s common stock.

The Vanguard Group has reported a 0% beneficial ownership in Dexcom Inc. common stock following an internal realignment that disaggregated reporting responsibilities.

The Vanguard Group reported a significant beneficial ownership stake of 12.61% in Dexcom Inc., holding 49.46 million shares as of September 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 8.3% of Dexcom Inc.'s common stock as of March 31, 2025.